The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1555
Lutetium Lu 177 Dotatate (Lutathera) for Gastroenteropancreatic Neuroendocrine Tumors (online only)
The full article is available to subscribers Subscriber Login   

The FDA has approved lutetium Lu 177 dotatate (Lutathera – Advanced Accelerator Applications), a radiolabeled somatostatin analog, for treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEPNETs) in adults.

MECHANISM OF ACTION — Lutetium Lu 177 dotatate binds to somatostatin receptors (with greatest affinity for subtype 2 receptors), including those found on somatostatin receptor-positive GEPNETs. After binding, the drug is internalized and induces cellular damage by delivering radionuclides directly to tumor and neighboring cells.

CLINICAL STUDIES — FDA approval of Lutathera was based on the results of two open-label trials (NETTER-1 and ERASMUS). In NETTER-1, 229 patients with inoperable locally advanced or metastatic midgut neuroendocrine tumors who had disease progression on standard-dose long-acting octreotide were randomized ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Lutetium Lu 177 Dotatate (Lutathera) for Gastroenteropancreatic Neuroendocrine Tumors (online only)
Article code: 1555f
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian